Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
0.6912
+0.0468 (7.26%)
Oct 27, 2026, 4:00 PM EDT - Market closed
Milestone Pharmaceuticals Revenue
Milestone Pharmaceuticals had revenue of $559.00K in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $2.34M. In the year 2025, Milestone Pharmaceuticals had annual revenue of $1.55M. That makes Milestone Pharmaceuticals the 42,067th largest company in the world by revenue and 5,699th in the United States.
Revenue (ttm)
$2.34M
Revenue Growth
n/a
P/S Ratio
41.57
Revenue / Employee
$61,658
Employees
38
Market Cap
97.40M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.55M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | -4.00M | -80.00% |
| Dec 31, 2022 | 5.00M | -10.00M | -66.67% |
| Dec 31, 2021 | 15.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| ImmuCell | 30.68M |
| Tonix Pharmaceuticals Holding | 29.10M |
| LENZ Therapeutics | 21.48M |
| Coya Therapeutics | 8.02M |
MIST News
- 7 days ago - Milestone Pharmaceuticals price target lowered to $5 from $6 at Raymond James - TheFly
- 8 days ago - Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences - GlobeNewsWire
- 18 days ago - Milestone Pharmaceuticals enrolls first European patient in ReVeRA-301 trial - TheFly
- 18 days ago - Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial - GlobeNewsWire
- 19 days ago - Milestone Pharmaceuticals management to meet virtually with Cantor - TheFly
- 4 weeks ago - Milestone announces Montreal Heart Institute enrolled first patient - TheFly
- 4 weeks ago - Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR - GlobeNewsWire
- 6 weeks ago - Milestone Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts